Across autoimmune, oncology, metabolic, and CNS, mAb, bispecific, trispecific, ADC, GPCR nanobody. All designed on AINN-P1 and wet-lab validated. Full data room under CDA.
CD122, TL1A, IL-23 p19, A4B7, BAFFR, FcRn, TMEM219, TSLP, IL-33, IL-13, IL-25, IL-36R, IL-18
CD122×TL1A, A4B7×IL-23, TSLP×IL-13, IL-25×IL-13, TMEM219×TL1A, IL-23×TL1A, BAFFR×TL1A, and additional combinations
IL-33 × TSLP × IL-13 · TSLP × IL-25 × IL-13
PD-L1, TROP2, VEGF, GPNMB, B7-H3, HHLA2, EPHA5, DLK1, MELTF, MUC16, DLL3, CD200, IGF2
PDL1×HHLA2, PDL1×EPHA5, DLK1×EPHA5, PDL1×DLK1, MELTF×VEGF, DLK1×VEGF
PDL1 × TROP2 × VEGF
PDL1×TROP2, TROP2×VEGF, PDL1×B7H3, PDL1×GPNMB, MELTF, DLK1×VEGF, PDL1×EPHA5, PDL1×DLK1
ActRII A/B, Myostatin, lead candidates advancing toward animal studies.
CD98 (BBB shuttle, animal discussions underway), Nogo-A, HMGB1, GDF15
GLP1R, GIPR, GCGR, CCR8, CCR5, CCR2, CXCR2–6, S1PR1, ADORA2A, MC4R, C5AR1, PAR2/4, and more
* Lead candidates advancing to animal studies. Stages shown are discovery through preclinical. No clinical-stage programs are represented on this summary. All affinities cited elsewhere on the site are from AINN-P1-designed campaigns measured by SPR or BLI. Full data available under CDA.
AINN-P1 is a 167M-parameter protein foundation model built for sequence-to-function prediction without requiring 3D modeling. Specialized downstream models support binding, immunogenicity, stability, and epitope mapping across every pipeline program above.
Pick any target or program above. Under CDA, we'll share binding data, FTO analysis, and the development plan within one week.
Request the data room →